Affordable Access

deepdyve-link
Publisher Website

Bladder cancer in patients after organ transplantation.

Authors
  • Wallerand, Hervé
  • Ravaud, Alain
  • Ferrière, Jean-Marie
Type
Published Article
Journal
Current Opinion in Urology
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Sep 01, 2010
Volume
20
Issue
5
Pages
432–436
Identifiers
DOI: 10.1097/MOU.0b013e32833cf1ef
PMID: 20644482
Source
Medline
License
Unknown

Abstract

The molecular pathway P13K/Akt/mTOR is frequently activated during human solid tumor development and progression. However, mTOR inhibitors are also used in order to avoid renal allograft rejection. The combination of both actions could significantly improve graft and organ recipient survival and could provide progresses in targeted therapy management of bladder cancer.

Report this publication

Statistics

Seen <100 times